CorMedix(CRMD) - 2025 Q3 - Quarterly Results

Filing Information This section provides essential identification and contact details for CorMedix Inc. as the registrant, along with the report's filing date Registrant Details This section provides the core identification details for CorMedix Inc. as the registrant, including its incorporation state, commission file number, IRS employer ID, principal executive offices, and contact information, along with the report date - Registrant: CORMEDIX INC., incorporated in Delaware[1] - Report Date: October 20, 2025[1] - Principal Executive Offices: 300 Connell Drive, Suite 4200, Berkeley Heights, New Jersey 07922[1] Securities Information This section details the registrant's securities registered under Section 12(b) of the Exchange Act and clarifies its status regarding emerging growth company provisions Securities Registered Under Section 12(b) | Title of each class | Trading Symbol | Name of exchange on which registered | | :------------------ | :------------- | :----------------------------------- | | Common Stock, $0.001 Par Value | CRMD | Nasdaq Global Market | - CorMedix Inc. is not an emerging growth company[3] Item 2.02 Results of Operations and Financial Condition This item reports the preliminary financial results for the recent quarter, emphasizing their provisional nature and attachment as an exhibit Preliminary Financial Results Announcement CorMedix Inc. announced its preliminary financial results for the quarter ended September 30, 2025, via a press release issued on October 20, 2025. These results are explicitly stated as preliminary and subject to adjustment upon completion of standard accounting procedures - CorMedix Inc. issued a press release on October 20, 2025, announcing preliminary financial results for the quarter ended September 30, 2025[4] - The preliminary results are subject to adjustment upon completion of accounting procedures[4] - The press release is attached as Exhibit 99.1 and incorporated by reference, furnished under Item 2.02 and Item 9.01[4][5] Item 9.01 Financial Statements and Exhibits This item provides a comprehensive list of all financial statements and supplementary exhibits included in the filing List of Exhibits This section lists the exhibits accompanying the Form 8-K filing, which include the press release detailing preliminary financial results and the interactive data file Exhibits Filed | Exhibit No. | Description | | :------------ | :----------------------------------------------------------------------- | | 99.1 | Press Release issued by CorMedix Inc., dated October 20, 2025. | | 104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). | SIGNATURES This section formally confirms the report's authorization and signing by an official representative of the registrant Authorization and Signing This section confirms the official signing of the report by an authorized representative of CorMedix Inc., fulfilling the requirements of the Securities Exchange Act of 1934 - The report was duly signed on behalf of CorMedix Inc. pursuant to the requirements of the Securities Exchange Act of 1934[9] - Signed by Joseph Todisco, Chief Executive Officer, on October 20, 2025[10][11]